Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference
Date:6/8/2011

NOVATO, Calif., June 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 15, 2011 at 10:00 a.m. CT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Jefferies Global Healthcare Conference
2. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
3. BioMarin Announces First Quarter 2011 Financial Results
4. BioMarin to Present at the Deutsche Bank Healthcare Conference
5. BioMarin to Present at the Barclays Global Healthcare Conference
6. BioMarin to Present at the Cowen Health Care Conference
7. BioMarin to Present at the Citi Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
10. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Cirujanos ... para ayudar a los médicos a compartir sus mejores ... a escala mundial. Profesionales médicos de Europa, África, ... han apuntado a la aplicación, que combina la transmisión ... entorno totalmente seguro. Educación   "Imagine ...
(Date:5/24/2016)... , May 24, 2016  NxStage Medical, Inc. ... company focused on advancing renal care, today announced that ... to participate in the following schedule of investor conferences. ... made available at http://ir.nxstage.com/ .   ... Jefferies Healthcare Conference NY, NY           Friday, June 10, ...
(Date:5/24/2016)... 2016 Les ... la première endoprothèse à double thérapie au ... portant sur les membres inférieurs et la ... entreprise mondiale spécialisée dans la fourniture de ... a élargi son portefeuille pour inclure des ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to ... which we as a society can control and change. , As nearly 795,000 Americans ... 40 seconds within the United States. Plus, with an estimated 129,000 of these people ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
(Date:5/26/2016)... ... ... last week’s media reports hinting at a June rate hike after the Federal Reserve’s ... interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at Georgia ... (FOMC) dot charts are of interest to the press for their noise potential,” Dhawan ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare industry ... for its inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., ... health of America’s healthcare providers. , The conference was highlighted by the announcement ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at ... offering a new model of care for living and healing, celebrated its grand opening, ... Life in a Real Home provided by Empowered Staff. , “This is an incredibly ...
Breaking Medicine News(10 mins):